Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

While it’s not too surprising that the Euphoria series finale got metaphorical and bent reality a bit, it does merit a quick recap into what and and did not happen. Spoilers ahead for Euphoria season ...

Spoiler alert! We're talking aboutthe biggest reveals in "Backrooms" (in theaters now) and the movie's ending, so turn away if you haven't seen it yet. The world of "Backrooms" isn't done expanding.

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Credit: A24 Dark closets ...

Bill Dubiel is a veteran writer, editor, and college professor based in Buffalo, NY. Formerly of Screen Rant, you can usually find him in a late-night double feature, including the newest horror movie ...

This article contains massive spoilers for "Backrooms." If you haven't seen the film, turn back now! To the uninitiated, Kane Parsons' "Backrooms" — both the new feature film and the popular, ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 14, 2026, Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals, Inc.

Add Yahoo as a preferred source to see more of our stories on Google. Too afraid to watch the movie? Allow us to explain. (Warning: spoilers ahead.) Out May 15 nationwide, the new movie from YouTuber ...

Be careful what you wish for. This idea, often explored in fiction, lies at the center of “Obsession,” Focus Features‘ new horror film from writer/director/editor Curry Barker. The movie follows Bear ...

Bill Dubiel is a veteran writer, editor, and college professor based in Buffalo, NY. Formerly of Screen Rant, you can usually find him in a late-night double feature, including the newest horror movie ...

"For 2026, we are maintaining our cash operating expense guidance of less than $390 million." (CFO & President of Recursion UK Taylor). "We expect multiple clinical readouts over the next 12 to 18 ...

Najat Khan looks at successful platform companies like Vertex, Regeneron and Alnylam and sees a path for Recursion to join them—if the company stays disciplined. (Recursion Pharmaceuticals) Chris ...